SCHEMBL5455553

SCHEMBL5455553

Cc1ccc2[nH]c3c(c2c1)CCCC3NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RB1 P06400 1/20 0.59
GAA P10253 1/20 0.55
CASP6 P55212 1/20 0.55
MAPT P10636 4/20 0.54
ALOX15 P16050 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
GLA P06280 1/20 0.54
MAPK1 P28482 1/20 0.53
PRMT5 O14744 2/20 0.52
SIRT1 Q96EB6 7/20 0.51
HTR2A P28223 2/20 0.51
HTR1A P08908 1/20 0.51
HTR7 P34969 1/20 0.51
HTR6 P50406 1/20 0.51
SIRT2 Q8IXJ6 3/20 0.50
RECQL P46063 1/20 0.50
DHODH Q02127 1/20 0.46
LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5445854 0.94 RB1 (0.63) RB1GAACASP6MAPTALOX15
SCHEMBL5458951 0.90 RB1 (0.59) RB1GAACASP6MAPTALOX15
SCHEMBL5455558 0.89 RB1 (0.53) RB1GAACASP6MAPTALOX15
SCHEMBL5449898 0.87 RB1 (0.56) RB1GAACASP6MAPTALOX15
SCHEMBL4025627 0.85 RB1 (0.59) RB1GAACASP6MAPTALOX15
SCHEMBL13772090 0.85 RB1 (0.59) RB1GAACASP6MAPTALOX15
SCHEMBL14361123 0.84 RB1 (0.56) RB1GAACASP6MAPTALOX15
SCHEMBL5456896 0.84 RB1 (0.56) RB1GAACASP6MAPTALOX15
SCHEMBL15577178 0.81 GAA (0.60) GAACASP6MAPTALOX15SMN1; SMN2
SCHEMBL15614787 0.81 GAA (0.60) GAACASP6MAPTALOX15SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 RB1 1821/4885GAA 1417/4885CASP6 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.